Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira (NASDAQ: PCRX) presented three real-world HOPD analyses at AMCP 2026 showing EXPAREL (liposomal bupivacaine) was associated with lower or comparable total healthcare costs and reduced opioid use in select cohorts through six months.
Key findings: THA costs were lower at 3 months ($7,332 vs $8,153) and 6 months ($13,022 vs $15,081); TKA showed comparable or lower costs, notably in teaching hospitals; a 3-year budget model projected −$117,868 per 1M members versus ropivacaine.
Pacira BioSciences (Nasdaq: PCRX) will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on April 15, 2026. Live audio and a replay (available for two weeks) can be accessed via the company events page.
Pacira also granted inducement equity awards on April 2, 2026: stock options aggregating 5,000 shares (10-year term, exercise price $22.70, four-year vesting) and restricted stock units aggregating 13,000 shares (four annual vesting installments beginning April 1, 2027). Awards were approved by the People & Compensation Committee under Nasdaq Rule 5635(c)(4).
Pacira BioSciences (NASDAQ: PCRX) presented two propensity score–matched real-world studies at ORS 2026 showing EXPAREL (liposomal bupivacaine) was associated with lower total cost of care versus ropivacaine and versus non-LB analgesia in TKA and spinal fusion. Reported benefits included lower 30-day total costs, reduced select resource use, and a shorter hospital length of stay in spinal fusion.
Summary not available.
Pacira BioSciences (Nasdaq: PCRX) responded to DOMA's nomination of three director candidates and reaffirmed its 5x30 strategy to drive long-term shareholder value. Key 2025 results: 2.5 million patients treated, EXPAREL volume +6.2% YoY, GAAP gross margin 79% (non-GAAP 81%), and $150 million share repurchases reducing shares from 47 to 41 million. The company highlighted expansion of its EXPAREL patent estate to 21 Orange-Book listed patents, progress in Phase 2 programs PCRX-201 and PCRX-2002, and several 2026 clinical milestones including a Phase 3 interim analysis and multiple topline readouts.
Summary not available.
Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards on March 3, 2026 to three new employees under its Amended and Restated 2014 Inducement Plan as permitted by Nasdaq Listing Rule 5635(c)(4).
One hire received options for 2,400 shares (10-year term, $22.10 exercise price, four-year vesting). Three hires received 5,500 RSUs vesting annually over four years beginning March 1, 2027.
Pacira BioSciences (NASDAQ:PCRX) will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 2:30 PM ET in Miami. Live audio will stream on the company Events page and a replay will be available for two weeks.
Pacira BioSciences (NASDAQ: PCRX) presented real-world IGOR registry data at AAOS 2026 showing benefits for EXPAREL and ioveraº in knee procedures and osteoarthritis pain. For TKA, liposomal bupivacaine (LB, n=42) showed lower acute NRS pain (3.9 vs 4.9; P<0.001), lower BPI-SF at 3 months (2.6 vs 2.9; P=0.03), and shorter hospital stays (15.0 vs 20.6 hours; P=0.007). Cryoneurolysis (n=129) was associated with sustained pain and functional improvements through 12 months (P<0.01) versus typical 4–6 month relief from intra-articular agents.
Findings derive from a multicenter, prospective, observational registry (IGOR) and were presented March 2, 2026 at AAOS.
Pacira BioSciences (Nasdaq: PCRX) reported Q4 2025 revenue of $196.9M and full-year revenue of $726.4M, led by EXPAREL sales of $155.8M in Q4 and $575.1M for 2025.
GAAP net income was $1.6M in Q4 and $7.0M for 2025; adjusted EBITDA was $38.7M in Q4 and $186.5M for the year. The company repurchased 5.9M shares for $150M in 2025 and provided 2026 guidance including EXPAREL sales of $600–$620M.